Can Longevity Become Public Policy?
Notas do episódio
Hosts:
Phil Newman: https://qrco.de/bgXpNY
Nina Patrick: https://qrco.de/bgXpKn
----------
Sponsor: FlexBeam
FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.
Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.
Link: rechargehealthas.sjv.io/jRQyQ5
----------
Guests: Dylan V. Livingston
Founder and CEO of The Alliance for Longevity Initiatives (A4LI)
LinkedIn: www.linkedin.com/in/dylan-v-livingston/
Website: a4li.org/
----------
What if the biggest barrier to longer, healthier lives isn't scientific discovery, but public policy?
In this episode, Phil Newman and Dr. Nina Patrick sit down with Dylan V. Livingston, founder and CEO of the Alliance for Longevity Initiatives (A4LI), to explore how Washington is becoming one of the most important frontiers in healthy aging.
Based on his unusual journey from political campaigning to longevity advocacy, Dylan explains why extending healthy lifespan requires more than innovative biotechnology. It also requires regulatory reform, stronger public investment, and policymakers who understand the biology of aging. From his work advancing state-level Right to Try legislation to proposals for new FDA pathways that recognize therapies targeting multiple age-related diseases, he shares how policy could dramatically accelerate the translation of longevity science into clinical practice.
The conversation explores the growing role of biomarkers, surrogate endpoints, and ARPA-H's PROSPR program in creating clearer regulatory pathways for aging interventions. Dylan also discusses proposals for expanding NIH support for aging biology research, why the current funding landscape remains misaligned with the burden of age-related disease, and how advocacy organizations can help bridge the gap between researchers, biotech companies, regulators, and elected officials.
They also examine whether the United States can maintain its leadership in longevity innovation as countries around the world invest in their own longevity ecosystems, and why creating the right incentives today could determine who leads the next generation of medicine.
In this episode, you’ll learn:
- Why public policy may become the biggest accelerator, or bottleneck, for longevity science.
- How a proposed multi-disease therapeutic designation could speed the development of aging interventions.- Why validated biomarkers and surrogate endpoints are essential for future FDA approval pathways.
- How Right to Try legislation could expand safe access to experimental longevity therapies while generating valuable clinical data.
- Why stronger NIH investment, regulatory reform, and grassroots advocacy are all needed to bring longevity medicine into mainstream healthcare.
If you want to understand how longevity is evolving from a scientific discipline into a healthcare and public policy movement, this episode explores the people, institutions, and regulatory decisions that could shape the future of healthy aging for decades to come.
Subscribe for weekly conversations exploring longevity science, biotechnology, preventative medicine, and the innovations transforming how we live longer and better.